WO2002070744A3 - Test de criblage de banque adénovirale destiné à des procédés et à des gènes régulateurs e2f, et compositions destinées au criblage de composés - Google Patents

Test de criblage de banque adénovirale destiné à des procédés et à des gènes régulateurs e2f, et compositions destinées au criblage de composés Download PDF

Info

Publication number
WO2002070744A3
WO2002070744A3 PCT/EP2002/002511 EP0202511W WO02070744A3 WO 2002070744 A3 WO2002070744 A3 WO 2002070744A3 EP 0202511 W EP0202511 W EP 0202511W WO 02070744 A3 WO02070744 A3 WO 02070744A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
screening compounds
regulatory genes
library assay
Prior art date
Application number
PCT/EP2002/002511
Other languages
English (en)
Other versions
WO2002070744A2 (fr
Inventor
Es Helmuth Hendrikus Gerar Van
Godefridus Augustinus Michiels
Peter Herwig Maria Tomme
Reginald Christophe Xavie Brys
Rene Bernards
Original Assignee
Galapagos Genomics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01870038A external-priority patent/EP1239038A1/fr
Application filed by Galapagos Genomics B V filed Critical Galapagos Genomics B V
Priority to AU2002253104A priority Critical patent/AU2002253104A1/en
Publication of WO2002070744A2 publication Critical patent/WO2002070744A2/fr
Publication of WO2002070744A3 publication Critical patent/WO2002070744A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne les domaines de la génétique moléculaire et de la médecine. Cette invention concerne notamment le domaine de la génomique fonctionnelle. Elle concerne aussi des procédés et des moyens d'identification d'acides nucléiques et des polypeptides codés par ces acides nucléiques présentant une fonction liée à la voie, lesquels ont été isolés lors d'un test de criblage à haut débit au moyen de l'activité du facteur de transcription E2F en tant qu'afficheur. Les composés identifiés sont des cibles de médicament convenant au traitement de maladies humaines.
PCT/EP2002/002511 2001-03-07 2002-03-06 Test de criblage de banque adénovirale destiné à des procédés et à des gènes régulateurs e2f, et compositions destinées au criblage de composés WO2002070744A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002253104A AU2002253104A1 (en) 2001-03-07 2002-03-06 Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP01870038.5 2001-03-07
EP01870038A EP1239038A1 (fr) 2001-03-07 2001-03-07 Essais à haut rendement pour l'identification de modulateurs de l'activité de E2F
US28259001P 2001-04-09 2001-04-09
US60/282,590 2001-04-09
EP01870095.5 2001-05-02
EP01870095 2001-05-02
EP01870124.3 2001-06-08
EP01870124 2001-06-08

Publications (2)

Publication Number Publication Date
WO2002070744A2 WO2002070744A2 (fr) 2002-09-12
WO2002070744A3 true WO2002070744A3 (fr) 2003-10-09

Family

ID=27440168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002511 WO2002070744A2 (fr) 2001-03-07 2002-03-06 Test de criblage de banque adénovirale destiné à des procédés et à des gènes régulateurs e2f, et compositions destinées au criblage de composés

Country Status (2)

Country Link
AU (1) AU2002253104A1 (fr)
WO (1) WO2002070744A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121778A2 (fr) 2004-06-14 2005-12-22 Galapagos N.V. Procedes d'identification, et composes utiles pour le traitement de maladies degeneratives et inflammatoires
EP2360474B1 (fr) 2004-06-21 2013-07-24 Galapagos N.V. Méthodes et moyens pour le traitement de l'ostéoarthrite
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8637257B2 (en) 2007-06-20 2014-01-28 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033819A1 (fr) * 1997-01-30 1998-08-06 New York University Recepteurs cellulaires des adenovirus du sous-groupe c et des virus coxsackie du groupe b
WO1999050405A1 (fr) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
WO1999054461A2 (fr) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre
WO1999055886A1 (fr) * 1998-04-24 1999-11-04 Genova Pharmaceuticals Corporation Decouverte de genes fonctionnels
WO1999060407A1 (fr) * 1998-05-15 1999-11-25 Cancer Research Campaign Technogoly Limited Analyses, techniques et dispositifs permettant de moduler l'activite de e2f
WO1999064582A2 (fr) * 1998-06-12 1999-12-16 Introgene B.V. Criblage de fonction genique a haut rendement a l'aide de banques d'applications genomiques fonctionnelles
US6048693A (en) * 1996-10-16 2000-04-11 Bittech, Inc. Phenotypic assays of cyclin/cyclin-dependent kinase function
WO2000056881A1 (fr) * 1999-03-23 2000-09-28 Human Genome Sciences, Inc. 48 proteines humaines secretees
WO2001004296A1 (fr) * 1999-07-12 2001-01-18 Mcgill University Polypeptides rbp1 et leurs utilisations

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048693A (en) * 1996-10-16 2000-04-11 Bittech, Inc. Phenotypic assays of cyclin/cyclin-dependent kinase function
WO1998033819A1 (fr) * 1997-01-30 1998-08-06 New York University Recepteurs cellulaires des adenovirus du sous-groupe c et des virus coxsackie du groupe b
WO1999050405A1 (fr) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
WO1999054461A2 (fr) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre
WO1999055886A1 (fr) * 1998-04-24 1999-11-04 Genova Pharmaceuticals Corporation Decouverte de genes fonctionnels
WO1999060407A1 (fr) * 1998-05-15 1999-11-25 Cancer Research Campaign Technogoly Limited Analyses, techniques et dispositifs permettant de moduler l'activite de e2f
WO1999064582A2 (fr) * 1998-06-12 1999-12-16 Introgene B.V. Criblage de fonction genique a haut rendement a l'aide de banques d'applications genomiques fonctionnelles
WO2000056881A1 (fr) * 1999-03-23 2000-09-28 Human Genome Sciences, Inc. 48 proteines humaines secretees
WO2001004296A1 (fr) * 1999-07-12 2001-01-18 Mcgill University Polypeptides rbp1 et leurs utilisations

Also Published As

Publication number Publication date
WO2002070744A2 (fr) 2002-09-12
AU2002253104A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO2005042716A3 (fr) Oligonucleotides se liant a des acides nucleiques
WO2005005604A3 (fr) Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
WO1999053040A3 (fr) Sequences d'acide nucleique humain provenant de tissu de tumeur ovarienne
WO2005030121A3 (fr) Composes, compositions et procedes
WO2003087368A3 (fr) Moyens et procedes pour la modulation specifique de genes cibles dans le snc et l'oeil, et procedes pour leur identification
WO2004047863A3 (fr) Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
WO2001004314A3 (fr) Molecules d'acide nucleique et autres molecules associees a la synthese et au metabolisme des sterols
WO1999055858A3 (fr) Sequences nucleotidiques humaines obtenues a partir d'un tissu tumoral du pancreas
WO2003016482A3 (fr) Genes de methyltransferase et leurs utilisations
WO2004013312A3 (fr) Genes associes a la biosynthese du tocopherol et utilisation de ceux-ci
WO1999066028A3 (fr) Genes pour la biosynthese d'epothilones
WO2006017355A3 (fr) Variants d'aprotinine ameliores
WO2005079367A3 (fr) Synthase d'acide gras (fas) schizochytrium et produits et procedes connexes
WO2005067648A3 (fr) Profilage spatial multiplex d'expression genique
WO2002048329A3 (fr) Caspase 3 derivee d'une membrane, compositions contenant cette caspase et procedes d'utilisation associes
WO2003076631A3 (fr) Produits geniques d'expression differenciee dans les tumeurs et leur utilisation
WO2004063213A3 (fr) Peptides ciblant des cellules tumorales et endotheliales, compositions et leurs utilisations
WO2005026205A3 (fr) Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
WO2002050285A3 (fr) Gene et proteine lies a une histone deacetylase
WO2002070744A3 (fr) Test de criblage de banque adénovirale destiné à des procédés et à des gènes régulateurs e2f, et compositions destinées au criblage de composés
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2000008134A3 (fr) SERINE PROTEASE DE HtrA HUMAINE
WO1999046375A3 (fr) Sequences d'acide nucleique humaines issues de tissus tumoraux prostatiques
WO2004056965A3 (fr) Acides nucleiques codant des cibles de medicaments antifongiques et leurs procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP